image
Healthcare - Biotechnology - NASDAQ - US
$ 1.02
-1.92 %
$ 14.4 M
Market Cap
-0.16
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one MBRX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.02 USD, Moleculin Biotech, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one MBRX stock under the base case scenario is HIDDEN Compared to the current market price of 1.02 USD, Moleculin Biotech, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one MBRX stock under the best case scenario is HIDDEN Compared to the current market price of 1.02 USD, Moleculin Biotech, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MBRX

image
$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5$0.0$0.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
0 REVENUE
0.00%
-26.6 M OPERATING INCOME
10.09%
-21.8 M NET INCOME
26.89%
-23.9 M OPERATING CASH FLOW
0.99%
-13 K INVESTING CASH FLOW
89.52%
4.64 M FINANCING CASH FLOW
-0.34%
63 K REVENUE
0.00%
-6.64 M OPERATING INCOME
6.90%
-1.88 M NET INCOME
82.23%
-5.08 M OPERATING CASH FLOW
16.85%
0 INVESTING CASH FLOW
0.00%
1 K FINANCING CASH FLOW
-99.98%
Balance Sheet Moleculin Biotech, Inc.
image
Current Assets 5.19 M
Cash & Short-Term Investments 4.28 M
Receivables 20 K
Other Current Assets 896 K
Non-Current Assets 11.7 M
Long-Term Investments 0
PP&E 424 K
Other Non-Current Assets 11.3 M
25.28 %5.29 %66.81 %Total Assets$16.9m
Current Liabilities 5.36 M
Accounts Payable 2.03 M
Short-Term Debt 0
Other Current Liabilities 3.33 M
Non-Current Liabilities 5.59 M
Long-Term Debt 0
Other Non-Current Liabilities 5.59 M
18.55 %30.41 %51.04 %Total Liabilities$10.9m
EFFICIENCY
Earnings Waterfall Moleculin Biotech, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 26.6 M
Operating Income -26.6 M
Other Expenses -4.88 M
Net Income -21.8 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)000(27m)(27m)5m(22m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-363.99% ROE
-363.99%
-128.58% ROA
-128.58%
-230.34% ROIC
-230.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Moleculin Biotech, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -21.8 M
Depreciation & Amortization 126 K
Capital Expenditures -13 K
Stock-Based Compensation 1.73 M
Change in Working Capital 231 K
Others -3.48 M
Free Cash Flow -23.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Moleculin Biotech, Inc.
image
MBRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Moleculin Biotech, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. globenewswire.com - 1 week ago
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of acute myeloid leukemia (AML); Interim data readout expected in the second half of 2025 HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization approved “naxtarubicin1” for the non-proprietary name of the Company's next-generation anthracycline in development, Annamycin. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases and the Company believes it may have the potential to treat additional indications. globenewswire.com - 2 weeks ago
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents Company continues to expand global IP coverage and claims to major markets, now extending to June 2040  HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the U.S. Patent and Trademark Office (USPTO) has granted two additional U.S. patents with claims covering Annamycin. U.S. patent number 12,257,261 titled, “Preparation of Preliposomal Annamycin Lyophilizate”, has claims covering methods of making liposomal Annamycin and U.S. patent 12,257,262 titled “Method of Reconstituting Liposomal Annamycin“, has claims covering methods of making liposomal Annamycin suspension. globenewswire.com - 2 weeks ago
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line therapies both in vitro and in vivo globenewswire.com - 3 weeks ago
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that an abstract regarding the Company's next-generation anthracycline, Annamycin , has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 , taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL. globenewswire.com - 1 month ago
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 1 month ago
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial – Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ara-C is referred to as “AnnAraC”) for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This Phase 3 “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East. globenewswire.com - 1 month ago
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Jason McCarthy - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. seekingalpha.com - 1 month ago
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update – Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025 globenewswire.com - 1 month ago
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. globenewswire.com - 2 months ago
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference On-demand video webcast now available here HOUSTON , March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it participated in the Virtual Investor "Top 5 for '25" On-Demand Conference. As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025. prnewswire.com - 2 months ago
8. Profile Summary

Moleculin Biotech, Inc. MBRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 14.4 M
Dividend Yield 0.00%
Description Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Contact 5300 Memorial Drive, Houston, TX, 77007 https://www.moleculin.com
IPO Date June 2, 2016
Employees 17
Officers Dr. John Paul Waymack M.D., Sc.D. Senior Chief Medical Officer Dr. Donald H. Picker Ph.D. Chief Scientific Officer Mr. Walter V. Klemp Co-Founder, Chairman, President & Chief Executive Officer Mr. Jonathan P. Foster CPA Executive Vice President & Chief Financial Officer Dr. Waldemar Priebe Ph.D. Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board